Agilent Technologies (NYSE:A) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of Agilent Technologies (NYSE:AGet Rating) from a buy rating to a strong-buy rating in a research report released on Thursday morning.

A number of other research firms have also weighed in on A. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $160.00 to $130.00 and set an equal weight rating for the company in a report on Monday, April 25th. Robert W. Baird lowered their price target on shares of Agilent Technologies from $170.00 to $161.00 in a report on Wednesday, February 23rd. Bank of America lowered their price target on shares of Agilent Technologies from $179.00 to $160.00 and set a buy rating for the company in a report on Wednesday, February 23rd. Cowen reduced their price objective on shares of Agilent Technologies from $187.00 to $178.00 and set an outperform rating on the stock in a research note on Wednesday, February 23rd. Finally, Truist Financial downgraded shares of Agilent Technologies from a buy rating to a hold rating in a research note on Tuesday, April 19th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Agilent Technologies has a consensus rating of Buy and an average target price of $163.08.

NYSE:A opened at $124.70 on Thursday. The company has a quick ratio of 1.64, a current ratio of 2.19 and a debt-to-equity ratio of 0.53. The company has a market cap of $37.46 billion, a P/E ratio of 31.07, a P/E/G ratio of 2.76 and a beta of 1.06. Agilent Technologies has a fifty-two week low of $112.64 and a fifty-two week high of $179.57. The firm’s 50 day moving average is $127.55 and its two-hundred day moving average is $140.07.

Agilent Technologies (NYSE:AGet Rating) last posted its quarterly earnings results on Tuesday, February 22nd. The medical research company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.04. Agilent Technologies had a net margin of 18.70% and a return on equity of 27.04%. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.66 billion. During the same quarter last year, the firm posted $1.06 earnings per share. Agilent Technologies’s revenue was up 8.1% on a year-over-year basis. Research analysts forecast that Agilent Technologies will post 4.86 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 27th. Investors of record on Tuesday, July 5th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.67%. The ex-dividend date is Friday, July 1st. Agilent Technologies’s dividend payout ratio is currently 21.32%.

In related news, SVP Michael Tang sold 1,210 shares of the stock in a transaction dated Friday, March 18th. The stock was sold at an average price of $136.21, for a total value of $164,814.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Associated Banc Corp increased its holdings in shares of Agilent Technologies by 2.9% during the 4th quarter. Associated Banc Corp now owns 2,554 shares of the medical research company’s stock valued at $408,000 after acquiring an additional 72 shares during the last quarter. Glassman Wealth Services grew its holdings in Agilent Technologies by 47.4% in the 4th quarter. Glassman Wealth Services now owns 230 shares of the medical research company’s stock valued at $37,000 after buying an additional 74 shares during the last quarter. Webster Bank N. A. grew its holdings in Agilent Technologies by 5.3% in the 4th quarter. Webster Bank N. A. now owns 1,606 shares of the medical research company’s stock valued at $256,000 after buying an additional 81 shares during the last quarter. Franklin Street Advisors Inc. NC grew its holdings in Agilent Technologies by 3.9% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 2,151 shares of the medical research company’s stock valued at $343,000 after buying an additional 81 shares during the last quarter. Finally, CENTRAL TRUST Co grew its holdings in Agilent Technologies by 4.0% in the 4th quarter. CENTRAL TRUST Co now owns 2,111 shares of the medical research company’s stock valued at $337,000 after buying an additional 82 shares during the last quarter.

Agilent Technologies Company Profile (Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

See Also

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.